Anticancer genes: inducers of tumour-specific cell death signalling

Trends in Molecular Medicine

Volumn 16, Issue 2, 2010, Pages 88-96

  Grimm, Stefan ^a   Noteborn, Mathieu ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; APOPTIN; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CURCUMIN; GEMCITABINE; GENE PRODUCT; INTERLEUKIN 24; MAPATUMUMAB; PACLITAXEL; PROTEIN HAMLET; PROTEIN NOXA; ROSCOVITINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; APOPTIN GENE; APOPTOSIS; AUTOPHAGY; BLADDER CANCER; BREAST CANCER; BREVININ 2R GENE; CANCER GENE THERAPY; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; E4PRF4 GENE; EHRLICH ASCITES TUMOR; GENE ISOLATION; GLIOBLASTOMA; HAMLET GENE; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MDA 7 GENE; MELANOMA; MITOSIS; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NOXA GENE; NS1 GENE; ORCTL3 GENE; OVARY CANCER; PAR 4 GENE; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SKIN PAPILLOMA; SOLID TUMOR; STOMACH CANCER; TRAIL GENE; TUMOR CELL; UTERINE CERVIX CARCINOMA; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; CELL DEATH; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 76549133159     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2009.12.002     Document Type: Review

References (94)

1. Irshad S., et al. Isolation of ORCTL3 in a novel genetic screen for tumor-specific apoptosis inducers. Cell Death Differ. 16 (2009) 890-898
2. Suzuki S., et al. Therapeutic potential of proapoptotic molecule Noxa in the selective elimination of tumor cells. Cancer Sci. 100 (2009) 759-769
3. Ghavami S., et al. Brevinin-2R(1) semi-selectively kills cancer cells by a distinct mechanism, which involves the lysosomal-mitochondrial death pathway. J. Cell. Mol. Med. 12 (2008) 1005-1022
4. Bruno P., et al. Family at last: highlights of the first international meeting on proteins killing tumour cells. Cell Death Differ. 16 (2009) 184-186
5. Zhu W., and Depamphilis M.L. Selective killing of cancer cells by suppression of geminin activity. Cancer Res. 69 (2009) 4870-4877
6. Weinstein I.B., and Joe A. Oncogene addiction. Cancer Res. 68 (2008) 3077-3080
7. Stempien-Otero A., et al. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J. Biol. Chem. 274 (1999) 8039-8045
8. Danen-Van Oorschot A.A., et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 5843-5847
9. Backendorf C., et al. Apoptin: therapeutic potential of an early sensor of carcinogenic transformation. Annu. Rev. Pharmacol. Toxicol. 48 (2008) 143-169
10. Zhang Y.H., et al. Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen. J. Virol. 78 (2004) 9965-9976
11. Leliveld S.R., et al. Apoptin induces tumor-specific apoptosis as a globular multimer. J. Biol. Chem. 278 (2003) 9042-9051
12. Danen-Van Oorschot A.A., et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 11 (2004) 564-573
13. Rohn J.L., et al. A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 277 (2002) 50820-50827
14. Maddika S., et al. Unscheduled Akt-triggered activation of cyclin-dependent kinase 2 as a key effector mechanism of apoptin's anticancer toxicity. Mol. Cell. Biol. 29 (2009) 1235-1248
15. Liu X., et al. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol. Ther. 14 (2006) 637-646
16. Nuesch J.P., et al. Viral proteins killing tumor cells: new weapons in the fight against cancer. Cancer Biol. Ther. 7 (2008) 1374-1376
17. Klanrit P., et al. Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle 7 (2008) 205-215
18. Heilman D.W., et al. Apoptin nucleocytoplasmic shuttling is required for cell type-specific localization, apoptosis, and recruitment of the anaphase-promoting complex/cyclosome to PML bodies. J. Virol. 80 (2006) 7535-7545
19. Danen-van Oorschot A.A., et al. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis in human tumor cells. J. Virol. 74 (2000) 7072-7078
20. Maddika S., et al. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J. Cell Sci. 118 (2005) 4485-4493
21. Schoop R.A., et al. Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line. Int. J. Cancer 109 (2004) 38-42
22. Olijslagers S.J., et al. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin. Pharmacol. Toxicol. 100 (2007) 127-131
23. Schoop, R.A. (2009) Apoptin gene therapy for head and neck cancer. PhD Thesis, Leiden University, Leiden, the Netherlands
24. Gingras M.C., et al. Cytoplasmic death signal triggered by SRC-mediated phosphorylation of the adenovirus E4orf4 protein. Mol. Cell. Biol. 22 (2002) 41-56
25. Shtrichman R., et al. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 10080-10085
26. Virshup D.M., and Shenolikar S. From promiscuity to precision: protein phosphatases get a makeover. Mol. Cell 33 (2009) 537-545
27. Kornitzer D., et al. Adenovirus E4orf4 protein induces PP2A-dependent growth arrest in Saccharomyces cerevisiae and interacts with the anaphase-promoting complex/cyclosome. J. Cell Biol. 154 (2001) 331-344
28. Robert A., et al. Adenovirus E4orf4 hijacks rho GTPase-dependent actin dynamics to kill cells: a role for endosome-associated actin assembly. Mol. Biol. Cell. 17 (2006) 3329-3344
29. Li S., et al. The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells. Oncogene 28 (2009) 390-400
30. Svensson M., et al. Conversion of alpha-lactalbumin to a protein inducing apoptosis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4221-4226
31. Mok K.H., et al. HAMLET, protein folding, and tumor cell death. Biochem. Biophys. Res. Commun. 354 (2007) 1-7
32. Hallgren O., et al. Apoptosis and tumor cell death in response to HAMLET (human alpha-lactalbumin made lethal to tumor cells). Adv. Exp. Med. Biol. 606 (2008) 217-240
33. Gustafsson L., et al. Changes in proteasome structure and function caused by HAMLET in tumor cells. PLoS ONE 4 (2009) e5229
34. Hallgren O., et al. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. Apoptosis 11 (2006) 221-233
35. Duringer C., et al. HAMLET interacts with histones and chromatin in tumor cell nuclei. J. Biol. Chem. 278 (2003) 42131-42135
36. Aits S., et al. HAMLET (human alpha-lactalbumin made lethal to tumor cells) triggers autophagic tumor cell death. Int. J. Cancer 124 (2009) 1008-1019
37. Su Z.Z., et al. The cancer growth suppressor gene mda-7 selectively induces apoptosis in human breast cancer cells and inhibits tumor growth in nude mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 14400-14405
38. Sauane M., et al. N-glycosylation of MDA-7/IL-24 is dispensable for tumor cell-specific apoptosis and "bystander" antitumor activity. Cancer Res. 66 (2006) 11869-11877
39. Gupta P., et al. BiP/GRP78 is an intracellular target for MDA-7/IL-24 induction of cancer-specific apoptosis. Cancer Res. 66 (2006) 8182-8191
40. Pataer A., et al. Adenoviral endoplasmic reticulum-targeted mda-7/interleukin-24 vector enhances human cancer cell killing. Mol. Cancer Ther. 7 (2008) 2528-2535
41. Lebedeva I.V., et al. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res. 63 (2003) 8138-8144
42. Su Z., et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10332-10337
43. Sauane M., et al. Autocrine regulation of mda-7/IL-24 mediates cancer-specific apoptosis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 9763-9768
44. Cornelis J.J., et al. Cancer gene therapy through autonomous parvovirus - mediated gene transfer. Curr. Gene Ther. 4 (2004) 249-261
45. Nuesch J.P., and Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12482-12487
46. El-Guendy N., and Rangnekar V.M. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp. Cell Res. 283 (2003) 51-66
47. Garcia-Cao I., et al. Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep. 6 (2005) 577-583
48. Nalca A., et al. Oncogenic Ras sensitizes cells to apoptosis by Par-4. J. Biol. Chem. 274 (1999) 29976-29983
49. Gurumurthy S., et al. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol. Cell. Biol. 25 (2005) 1146-1161
50. Chakraborty M., et al. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61 (2001) 7255-7263
51. Goswami A., et al. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol. Cell 20 (2005) 33-44
52. Joshi J., et al. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J. 27 (2008) 2181-2193
53. Burikhanov R., et al. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138 (2009) 377-388
54. Walczak H., et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
55. Sheridan J.P., et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277 (1997) 818-821
56. Zhang X.D., et al. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 482 (2000) 193-199
57. Zhang X.D., et al. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59 (1999) 2747-2753
58. Ricci M.S., et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell. Biol. 24 (2004) 8541-8555
59. Wang Y., et al. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 5 (2004) 501-512
60. Koschny R., et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 45 (2007) 649-658
61. Mossberg A.K., et al. Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int. J. Cancer 121 (2007) 1352-1359
62. Aits S. HAMLET kills tumor cells; structure, cellular targets and therapeutic agents. In: Backendorf C., et al. (Ed). Proteins Killing Tumour Cells (2009), Research Signpost pp. 51-60
63. Gopalan B., et al. MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol. Cancer 6 (2007) 11
64. Eager R., et al. Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin. Biol. Ther. 8 (2008) 1633-1643
65. Emdad L., et al. Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol. Ther. 8 (2009) 391-400
66. Sarkar D., et al. Acquired and innate resistance to the cancer-specific apoptosis-inducing cytokine, mda-7/IL-24: not insurmountable therapeutic problems. Cancer Biol. Ther. 7 (2008) 109-112
67. Ganten T.M., et al. Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer. J. Mol. Med. 87 (2009) 995-1007
68. Johnstone R.W., et al. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer 8 (2008) 782-798
69. Festa M., et al. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-κB pathway. Int. J. Cancer 124 (2009) 2728-2736
70. Bellail A.C., et al. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 4 (2009) 34-41
71. Moretto P., and Hotte S.J. Targeting apoptosis: preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opin. Investig. Drugs 18 (2009) 311-325
72. Cool R.H. Receptor-specific variants of cytokine TRAIL with improved apoptotic characteristics. In: Backendorf C., et al. (Ed). Proteins Killing Tumour Cells (2009), Research Signpost 39-50
73. Visser A.E. Viral protein apoptin as a modulator tool and therapeutic bullet: implications for cancer control. Future Virol. 2 (2007) 519-527
74. Qu S., and Noteborn M.H.M. Preclinical studies on apoptin unravels its specific anticancer therapy potential. In: Backendorf C., et al. (Ed). Proteins Killing Tumour Cells (2009), Research Signpost 191-206
75. Sun J., et al. PTD4-apoptin protein therapy inhibits tumor growth in vivo. Int. J. Cancer 124 (2009) 2973-2981
76. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
77. Harada H., et al. Antitumor protein therapy; application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 13 (2006) 16-26
78. Zhao Y., et al. Cancer resistance in transgenic mice expressing the SAC module of Par-4. Cancer Res. 67 (2007) 9276-9285
79. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 (2008) 1001-1012
80. Zhou Y., et al. Fusion protein of adenovirus E4orf4 and human epidermal growth factor inhibits tumor cell growth. Int. J. Cancer 125 (2009) 1186-1192
81. Tahara I., et al. Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol. Ther. 15 (2007) 1805-1811
82. Yan S., et al. Recombinant human interleukin-24 suppresses gastric carcinoma cell growth in vitro and in vivo. Cancer Invest. 28 (2010) 85-93
83. Oida Y., et al. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol. Cancer Ther. 4 (2005) 291-304
84. Inoue S., et al. MDA-7/IL-24-based cancer gene therapy: translation from the laboratory to the clinic. Curr. Gene. Ther. 6 (2006) 73-91
85. Tong A.W., et al. Intratumoral injection of INGN 241, a nonreplicating adenovector expressing the melanoma-differentiation associated gene-7 (mda-7/IL24): biologic outcome in advanced cancer patients. Mol. Ther. 11 (2005) 160-172
86. Labrinidis A., et al. Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. Clin. Cancer Res. 15 (2009) 1998-2009
87. Andrzejewski T., et al. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res. 17 (2008) 257-267
88. Jin H., et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin. Cancer Res. 14 (2008) 7733-7740
89. Bremer E., et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol. Ther. 16 (2008) 1919-1926
90. Holoch P.A., and Griffith T.S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol. 625 (2009) 63-72
91. Fox N.L., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy. Expert Opin. Biol. Ther. 10 (2010) 1-18
92. Zong W.X., and Thompson C.B. Necrotic death as a cell fate. Genes Dev. 20 (2006) 1-15
93. Lemasters J.J. V. Necrapoptosis and the mitochondrial permeability transition: shared pathways to necrosis and apoptosis. Am. J. Physiol. 276 (1999) G1-G6
94. Sperandio S., et al. An alternative, nonapoptotic form of programmed cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 14376-14381